Our patient hasbeen diagnosed with non-kinetic AChR deficiency and the case is important with the detection of a new mutation.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Congenital myasthenic syndromes (CMS) are neuromuscular hereditary diseases with the symptoms of fatigue, weakness, ptosis,ophthalmoparesis and respiratory problems.
📊
Key Findings & Data:Here, we present a case who was thirteen years old and had a CHRNE genotype p.Y124 *(c.372C> G) homozygousmutation, which is associated with weakness, low voice, ophthalmoparesis and frequent respiratory infection since birth.
💡
Conclusion & Impact:Our patient hasbeen diagnosed with non-kinetic AChR deficiency and the case is important with the detection of a new mutation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Congenital myasthenic syndromes (CMS) are neuromuscular hereditary diseases with the symptoms of fatigue, weakness, ptosis,ophthalmoparesis and respiratory problems. This disease group is classified as CMS originating from the presynaptic region, synaptic gap andpostsynaptic region according to the origin of the neuromuscular junction. Most of these patients are affected by receptor defects originatingfrom the postsynaptic gap. Here, we present a case who was thirteen years old and had a CHRNE genotype p.Y124 *(c.372C> G) homozygousmutation, which is associated with weakness, low voice, ophthalmoparesis and frequent respiratory infection since birth. Our patient hasbeen diagnosed with non-kinetic AChR deficiency and the case is important with the detection of a new mutation.
🔖
Cite This Article
TEKİN, H. G., YILMAZ, S., AKTAN, G., GÖKBEN, S. (2019). De Novo CHRNE Mutation: Congenital Myasthenic Syndrome. The Journal of Pediatric Research, Cilt: 6 - Sayı: 4, 356–358. https://ajindex.com/articles/362986
Schara U, Della Marina A, Abicht A. Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics 2012;43: 184-93
Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015;14:420-34
Engel AG. Current Status of the Congenital Myasthenic Syndromes. Neuromuscul Disord 2012;22:99-111
Finlayson S, Beeson D, Palace J. Congenital myasthenic syndromes: an update. Pract Neurol 2013;13:80-91
Dilena R, Abicht A, Sergi P, et al. Congenital myasthenic syndrome due to choline acetyltransferase mutations in infants: clinical suspicion and comprehensive electrophysiological assessment are important for early diagnosis. J Child Neurol 2014;29:389-93
Yiş U, Becker K, Kurul S, et al. Genetic landscape of congenital myasthenic syndromes from Turkey: Novel mutations and clinical insights. J Child Neurol 2017;32:759-65
Engel AG, Ohno K, Milone M, et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 1996;5:1217-27
Webster R, Liu WW, Chaouch A, Lochmuller H, Beeson D. Fast-channel congenital myasthenic syndrome with a novel acetylcholine receptor mutation at the a–e subunit interface. Neuromuscul Disord 2014; 24: 143-7
Salih MA, Oystreck DT, Al-Faky YH, et al. Congenital myasthenic syndrome due to homozygous CHRNE mutations: report of patients in Arabia. J Neuroophthalmol 2011;31:42-7
Engel AG, Ohno K, Bouzat C, Sine SM, Griggs RC. End-plate acetylcholine receptor deficiency due to nonsense mutations in the epsilon subunit. Ann Neurol 1996;40:810-7
Burke G, Cossins J, Maxwell S, et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscul Disord 2004;14:356-64.